Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
October 31 2023 - 4:03PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage
biotechnology company and leader in the discovery and development
of novel therapeutics for the treatment of fibrotic diseases, today
announced three presentations at the upcoming 38th Annual Meeting
of the Society for Immunotherapy of Cancer (SITC) taking place
November 1 - 5, 2023 at the San Diego Convention Center in San
Diego, California.
Abstract Number 1467
Selective targeting of
integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic
cancer to improve the overall anti-tumor response
Date and Time: Friday, November 3rd
9:00 a.m. PTLocation: Poster Hall (Exhibit Hall B)
Abstract Number 714
Phase 1a trial of PLN-101095,
an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in
combination with pembrolizumab, in treatment-resistant patients
with advanced or metastatic solid tumors
Date and Time: Saturday, November 4th
9:00 a.m. PTLocation: Poster Hall (Exhibit Hall B)
Abstract Number 464
Integrin αvβ1 is Expressed in
Multiple Solid Tumor Types and Drives the Adhesion of Cancer
Associated Fibroblast to Latent TGF-β
Date and Time: Saturday, November 4th
9:00 a.m. PTLocation: Poster Hall (Exhibit Hall B)
Posters will be made available on the Publications page of the
Pliant website.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical
company and leader in the discovery and development of novel
therapeutics for the treatment of fibrotic diseases. Pliant's lead
product candidate, bexotegrast (PLN-74809), is an oral, small
molecule, dual selective inhibitor of αvß6 and αvß1 integrins that
is in development in the lead indications for the treatment of
idiopathic pulmonary fibrosis, or IPF, and primary sclerosing
cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical-stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social
media Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," and similar expressions (as well as other
words or expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
These statements include those regarding the safety, tolerability,
pharmacodynamics and therapeutic potential of bexotegrast; our
plans for the future development of bexotegrast; bexotegrast’s
potential to become a treatment for IPF or PSC; the anticipated
timing of data and progress from our clinical studies; including
the timing of 12-week and 24-week data from the 320 mg dose cohort
of the INTEGRIS-PSC Phase 2a trial in the first quarter of 2024 and
mid-2024, respectively. Because such statements deal with future
events and are based on our current expectations, they are subject
to various risks and uncertainties and actual results, performance
or achievements of Pliant Therapeutics could differ materially from
those described in or implied by the statements in this press
release. These forward-looking statements are subject to risks and
uncertainties, including those related to the development and
commercialization of our product candidates, including any delays
in our ongoing or planned preclinical or clinical trials, the
impact of current macroeconomic and marketplace conditions, our
reliance on third parties for critical aspects of our development
operations, the risks inherent in the drug development process, the
risks regarding the accuracy of our estimates of expenses and
timing of development, our capital requirements and the need for
additional financing, including the availability of additional term
loans under our loan facility, and our ability to obtain and
maintain intellectual property protection for our product
candidates. These and additional risks are discussed in the
sections titled "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in our
Quarterly Report on Form 10-Q for the period ended June 30, 2023
which is available on the SEC's website at www.sec.gov. Unless
otherwise noted, Pliant is providing this information as of the
date of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From May 2023 to May 2024